By Aran Sullivan
THE IDEA
The brain is constantly firing and controlling purposeful action potentials—electronic messages used by neurons to communicate with each other and allow the brain to function.Conversely, thewayspontaneous neural communication happens in the brainto makeuse ofa different process., William Stokes Chair in Experimental Therapeutics and chair of pharmacology, and postdoctoral researcherBarisAltenworked with,Aileen M. Lange and Annie Mary Lyle Chair of Cardiovascular Research and professor of pharmacology, to discoverthe mechanism of one of themodulation pathwaysinvolved inspontaneous signaling, which has therapeutic potential for several neurological diseases.

Theresearchersused stateoftheart electrophysiology and live-cell imaging techniques to discover themechanisms underlying howa neurotransmitter receptor sitecalled a GABA receptorinhibits or suppressesspontaneousneurotransmitterrelease. Importantly, thisinhibitionmechanism is different than that forneurotransmitter releaseevokedbyaction potentials, which depend on factors such as calcium signaling.
WHY IT MATTERS
“The modulation of neurotransmitter release through different methods is clinically beneficial in a wide variety of disorders,including epilepsy and depression,” said, a graduate student in the Kavalalilab and second author of the study.
Earlier has shown that the spontaneous release process can be targeted by rapid-action antidepressants and treatment of other neurological diseases. Knowing the mechanism of action for spontaneous release is critical for creating new drugs that can target that process. “Often, we need to be able to target only one mechanism, such as the spontaneous release of a neurotransmitter, while leaving other mechanisms intact,” Guzikowski said.

WHAT’S NEXT
“There is a critical need to better understand how spontaneous release is regulated to develop therapeutics that can selectively inhibit evoked versus spontaneous action potentials,” Guzikowski said. “This study sets the stage for future therapeutic approaches specifically targeting a single form of release.” The research also identifies a new target for neurotherapeutic interventions that should be investigated.
FUNDING
This research was supported by the National Institutes of Health.
GO DEEPER
The study, “,” was published in the journalCell Reportson Jan.18, 2022.